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Abstract 
 
Objectives: To determine etravirine (ETR) concentrations in cerebrospinal fluid (CSF) 
in HIV-infected patients. 
Methods: Twelve HIV-1 adult antiretroviral-experienced patients receiving an 
ETR-containing regimen for at least 1 month were enrolled. Both CSF and blood 
samples were taken around 12 h after the last ETR dose. LC/MS/MS  was used to 
determine ETR concentrations, and HIV-1 viral load was determined by real-time PCR, 
(LOD, 40 copies/mL). 
Results: Twelve blood and 12 CSF samples were collected. Median CD4 count was 
333 (84-765) cells/uL and median HIV-1 viral load was <40 (<40-1777) copies/mL. 
Median time on ETR was 42.4 weeks (4-140).  
Median ETR concentration in plasma was 611.5 (148-991) ng/mL. Median CSF ETR 
concentration was 7.24 (3.5-17.9) ng/ml; in all cases, values were above the IC50 range 
(0.39-2.4ng/ml). Median ETR CSF:plasma ratio was 0.01 (0.005-0.02). CSF viral load 
was > 40 copies/mL in one patient and plasma VL was still detectable after only 4 
weeks of therapy. 
Conclusions: ETR achieves concentrations several times above the IC50 range in 
CSF. All patients with undetectable plasma viral load were virologically suppressed in 
CSF while receiving an ETR-containing regimen. ETR may help in controlling HIV-1 in 
CNS. 
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Introduction 
Neurocognitive impairment seems to be a frequent event in HIV-1-infected patients 
despite the advent of cART1. Patients with symptomatic HIV encephalopathy have 
increased viral replication within the central nervous system (CNS), but apparently even 
low-level viral replication in this reservoir while on combined antiretroviral therapy can 
promote local immune activation, an inflammatory response, and subsequent brain 
damage.1,2 Moreover, the CNS may act as a separate viral reservoir, where HIV-1 
strains with a different resistance pattern to that of plasma HIV-1 strains may be found.3 
Good penetration of antiretroviral (ARV) drugs into the cerebrospinal fluid, a suggested 
surrogate CNS marker, has been associated with a decrease in viral replication and an 
improvement in neurocognitive alterations assessed by neuropsychological tests3. 
Cerebrospinal fluid (CSF) penetration can vary between the different ARV compounds. 
Most nucleoside analogues (with the exception of tenofovir) and the non-nucleoside 
reverse transcriptase inhibitor (NNRTI) nevirapine penetrate well4, as shown in previous 
studies. Efavirenz concentrations in the CSF are only 0.5% of plasma concentrations 
but exceed the wild-type IC(50) in nearly all individuals 5, whereas penetration is 
variable in the case of protease inhibitors. Indinavir achieves good concentrations, and 
darunavir and lopinavir fair concentrations, while atazanavir is associated with lower 
concentrations, although it has been suggested that IP levels would suffice to inhibit 
viral replication in some cases. 
New ARV drugs approved over the last few years have led to the design of effective and 
well-tolerated regimens for naïve and experienced patients. RGV (raltegravir) exceeded 
the IC95 levels reported to inhibit wild-type strains in a proportion of studied samples 
while darunavir concentrations were detectable in all assessed samples; most of the 
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latter exceeded or were in the same range as levels needed to inhibit replication of the 
wild-type virus6. Finally, maraviroc CSF concentrations were several times above the 
median IC90 in two groups of HIV-infected patients7.  
Data on the distribution of etravirine (ETR) into human compartments other than plasma 
has not been published to date, but extremely high protein binding means extensive 
penetration is not to be expected. Interestingly, the addition of ETR to a 
tenofovir/abacavir/saquinavir/lopinavir/ritonavir regimen was associated with an 
improvement in a patient with acute HIV meningoencephalitis8.  
 
 
Patients and Methods 
Twelve asymptomatic HIV-infected ARV pre-treated adult patients were enrolled in our 
HIV outpatient unit. In five of these patients, CSF maraviroc concentrations were also 
assessed8. All subjects had been taking ETR for at least 4 weeks as part of an ARV 
regimen. ETR dosage was set according to recommendations in the European 
Medicines Agency (EMA) scientific report9. Blood samples were obtained from each 
patient by peripheral venous puncture and CSF samples by lumbar puncture. All 
samples were centrifuged and frozen at -70°C until analysis. Both blood and CSF 
samples were taken approximately 12 hours after the previous ETR dose, in order to 
obtain the lowest ETR concentration.   
The study was approved by the hospital ethics committee and the Spanish Drug 
Agency, and patients gave written informed consent to participate.  
Total ETR concentrations in plasma and CSF samples were analyzed by liquid 
chromatography tandem mass spectrometry (LC/MS/MS), using positive turbo ion spray 
mode (Tandem Labs-New Jersey, 115 Silvia Street West Trenton, NJ 08628). The ion 
transition monitored was 514.1/389.1. The reverse-phase chromatography calibration 
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range was 0.250-1000 ng/mL in Li heparin plasma samples. The extraction procedure is 
based on protein precipitation with acetonitrile, using 50 µL of plasma. The internal 
standard was the stable isotope label for ETR.  
HIV-1 viral load was quantified with a real-time PCR  technique (Abbot Molecular Inc, 
Des Plaines, IL), performed according to the manufacturer's recommendations. The 
limit of detection of the method was 40 copies/mL.  
 
Results 
Eleven patients (91%) were men, and the mean age was 49.9 years. Median HIV-1 viral 
load was <40 (<40-1777) copies/mL and median CD4 count was 333 (84-765) cells/uL. 
Patients were receiving ETR for a median period of 34 (4-140) weeks. The 
pharmacokinetic and virologic data, and the ARV regimens received, are summarized in 
Table 1. Raltegravir (RGV) was given in 66% of cases, darunavir (DRV) in 58%, and 
maraviroc (MVC) in 41%. Nucleosides/tides were present in less than half of patients.  
ETR dosage was 400 mg/day and two patients were taking this dosage once a day.  
Median time period post dose was 12.5 hs (3 -16 hs). 
In all samples, ETR concentrations exceeded the IC50 range (0.39-2.4ng/ml). Median 
ETR plasma concentration was 661.5 (148-991) ng/ml and median ETR CSF 
concentration was 7.24 (3.5-17.9) ng/ml. The median ETR CSF:plasma ratio was 0.01 
(0.005-0.02) and the ETR CSF:estimated free plasma concentration (0.1% of the total 
ETR concentration) ratio was 12.06.  
Plasma HIV-1 viral load was detectable (192 and 1777 copies/ml) only in two patients, 
one of whom had CSF VL below 40 copies/ml while the other had 111 copies/ml. These 
two patients had been receiving 4-drug ETV-containing regimens for 16 and 4 weeks, 
respectively. They had shown a very good initial virological response (viral load 
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reduction of 1.9-2.8 log), but still had detectable plasma HIV-1 RNA levels at the time of 
the study.  
 
Discussion 
As expected, ETR plasma concentrations in all patients were several times higher than 
the IC50 range. Moreover, ETR CSF concentrations were above this value in all 
patients. It should be taken into account that almost all the drug in CSF is protein 
unbound and therefore active. Thus, the minimal drug concentration needed to inhibit 
50% of the virus in CSF would likely be even lower. Furthermore, the use of triple ARV 
therapy with CSF-penetrating drugs would assure sufficient antiviral activity in this 
reservoir.  
This data is in accordance with results from a study recently presented by Best et al. at 
an international meeting which showed that median ETR concentration in 9 patients 
was 9.5 ng/ml (6.4-26.4)10. However, in that study plasma and CSF samples were taken 
at a median of 4.8 hs (2.9-5.7) and 4.9 hs (2.6-5.5) after the last ETR dose, 
respectively. All samples were therefore taken near the ETR Cmax, making it difficult to 
know whether levels would remain higher than the IC50 until the next dose of the drug.  
ETR is extensively bound (99.9%) to albumin and alpha1-acid glycoprotein, suggesting 
a poor presence in CNS. However, the fact that ETR CSF concentrations were several 
times higher than the protein-unbound percentage of plasma concentrations suggests 
that ETR penetrates the Blood Brain Barrier (BBB) mainly by transcellular diffusion due 
to its lipid solubility.  
Interestingly, p-glycoprotein expressed in BBB is inhibited by ETR, but a clinically 
significant reduction of its activity would be achieved only with much higher ETR 
concentrations than those expected in human plasma. On the other hand, ETR is not a 
substrate of P-glycoprotein efflux pump. 
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Our observations provide evidence suggesting a role for ETR in the treatment of HIV-1 
in the CNS. Moreover, the fact that nine out of the twelve patients were receiving a 
nucleoside-sparing regimen (n:6) or tenofovir (a drug with a known low CNS 
penetration) as the only nucleotide (n:3) reinforces the likelihood that sufficient antiviral 
activity can be generated in this compartment by combining drugs with at least some 
CSF penetration.   
Knowledge is still very limited in this field, however, and many unanswered questions 
remain, such as the clinical significance of drug penetration into CSF and the number of 
penetrating drugs needed to reach viral suppression.  
It has been suggested that even low-level CSF viral replication of under 40 copies/mL 
may be associated with continuous immune activation and subsequent brain damage.1 
However, despite these controversial data, the available evidence suggests that good 
penetration of ARV drugs into the CNS may help to prevent and improve neurocognitive 
disturbances in patients with a chronic disease, as well as inhibiting] viral 
dissemination into the CNS in the initial phases of infection.1  
Conclusion 
Our data suggest that ETR may contribute to inhibit HIV-1 replication in CNS and that 
combined nucleoside-sparing regimens, including new ARV drugs, seem to be locally 
active.   
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  N 
 PlasmaVL 
(copies/ml) 
 CSF VL 
(copies/ml) 
CD4 
(cel/ul) 
Weeks on 
ETR 
PlasmaConc 
(ng/mL 
CSFConc 
(ng/mL 
CSF:Plasma 
Ratio 
Concomitant ARV 
Treatment 
2 <40 <40 221 5 991 7,58 0,007 RGV-MVC-DRVr 
3 1777 111 120 4 666 6,99 0,01 RGV-MVC-DRVr 
4 <40 <40 231 58 281 3,67 0,01 RGV-MVC-DRVr 
5 <40 <40 384 50 277 8,24 0,03 RGV-MVC-DRVr 
9 <40 <40 486 140 148 3,82 0,02 RGV-DRVr 
1 <40 <40 759 24 589 5,89 0,01 RGV-MVC 
6 192 <40 330 16 421 7,05 0,016 RGV-DRVr-TDF* 
8 <40 <40 84 92 705 17,9 0,02 RGV-TDF 
12 <40 <40 153 12 697 8,33 0,01 DRVr-TDF 
7 <40 <40 459 44 669 16,4 0,02 TDF/FTC 
10 <40 <40 336 52 531 7,43 0,01 AZT-ddI 
11 <40 <40 765 12 634 3,59 0,005 ABC-3TC* 
 
Median: 
<40 
Median: 
<40 
Median: 
333 
Median: 
34 
Median: 
611,5 
Median: 
7,24 
Median: 
0,01  
Table 1. Pharmacokinetic, virological and therapeutic data of enrolled patients  
Abbreviations: CSF, cerebrospinal fluid; VL, viral load;  Conc., concentration; ARV, antiretroviral;ddI, didanosine; ETR, 
etravirine; DRVr, darunavir/ritonavir; TDF, tenofovir; AZT, zidovudine; ABC, abacavir; FTC, emtricitabine; 3TC 
lamivudine,  MVC, maraviroc; RGV, raltegravir. 
* Patient receiving ETR once a day. 
            
 
 
 
 
 
 
 
 
 
Figure 1. Plasma and CSF concentrations of etravirine 
